NextGen Biomed 2026. March 24 2026 - March 25 2026 KCAS Bio will be attending NextGen Biomed 2026 in London, on March 24 - 25, 2026. NextGen Biomed is a long-standing, community-driven platform that brings together the biologics and immunotherapy ecosystem to foster interdisciplinary collaboration and knowledge sharing across the R&D lifecycle. Supporting biologics drug development. KCAS Bio supports biologics drug development across preclinical and clinical stages with integrated bioanalytical and biomarker solutions. Its capabilities include support for advanced modalities such as antibody - drug conjugates, cell and gene therapies, bispecific antibodies, and targeted protein degraders, with expertise in pharmacokinetics, biomarkers, immunogenicity, and advanced flow cytometry to enable robust, decision-ready data. Connect with KCAS Bio in London. Kcas, Llc invite you to connect with KCAS Bio to discuss how its bioanalytical expertise can support your research and development programs. Whether you are addressing technology transfer challenges, advancing complex modalities, or preparing for clinical development, its teams are ready to support your objectives. Contact Kcas, Llc to schedule a meeting. Date: March 24 - March 25 Organizer: Oxford Global Address: QEII Centre, London, UK Add to calendar: Meet Kcas, Llc at this event

KCAS Bio receives Scientist.com Supplier Recognition Award for 2025. KCAS Bio December 18, 2025 KCAS Bio has officially received the Scientist.com Supplier Recognition Award for outstanding performance in offering drug discovery research services on their R&D sourcing platform for 2025. KCAS Bio's contibutions were recognized to enhance research efficiency worldwide. This award was evaluated based on responsiveness - the time it takes to respond to client requests; marketplace activity - the number of requests received/fulfilled; and customer satisfaction - star ratings posted by researchers following completed requests. * In Vitro Assays * Chemical and Compound Analysis * Discovery Chemistry * Biomarkers * Protein Sciences KCAS Bio is thrilled to be a valued partner for 2025 and looking forward to 2026. Learn more about all the services offered at KCAS Bio by filling out the form below.

KCAS Bio strengthens Board of Directors with appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle. KCAS Bio November 3, 2025 OLATHE, Kan. - (BUSINESS WIRE) - KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. Their addition marks a significant milestone in KCAS Bio's continued growth and strategic evolution in the global life sciences industry. KCAS Bio is headquartered in the Kansas City, Kansas metropolitan area with operating sites in the greater Philadelphia area; Lyon, France; and a partnership in Melbourne, Australia. The Company is backed by Vitruvian Partners, one of the world's leading growth-focused investment firms. Dr. Paul Kirchgraber brings decades of leadership experience in clinical research and laboratory operations. He served as Executive Vice President and CEO of Covance, Labcorp's Drug Development Division, where he led global teams in drug and medical device development in over 60 countries. Dr. Kirchgraber has experience running global pre-clinical, central and bioanalytical labs as well as phase one through four clinical services. He also served as Chairman of the Association of Clinical Research Organizations. His expertise in laboratory medicine and strategic operations will be instrumental in guiding KCAS Bio's scientific and business initiatives. Mr. Kurt Doyle is a seasoned executive with deep experience in commercial strategy and business development within the pharmaceutical and biotech sectors. He has spent 26 years at IQVIA, most recently as Senior Vice President - Large Pharma and Specialty Services, where he drove growth through client engagement, operational excellence, and strategic partnerships. Mr. Doyle's insights into market dynamics and customer needs will support KCAS Bio's mission to deliver high-quality, client-focused solutions across the drug development continuum. "We are thrilled to welcome Paul and Kurt to our Board," said John Bucksath, CEO of KCAS Bio. "Their combined experience and leadership will be invaluable as we continue to expand our capabilities and deliver innovative solutions to our clients. Their strategic vision aligns perfectly with our commitment to scientific excellence and operational excellence." Sophie Bower-Straziota, Partner at Vitruvian Partners, commented, "KCAS Bio has grown tremendously since we backed John and his team. We are delighted to welcome Paul and Kurt to the Board to support KCAS Bio's continued expansion in its ability to serve the world's largest pharma companies and biotechs in accelerating time to market for their most valuable therapeutics." The appointments of Dr. Kirchgraber and Mr. Doyle reflect KCAS Bio's dedication to building a world-class leadership team to support its mission of accelerating life-changing therapies to market. Interested in getting in touch? Please fill out the form below!